Conclusion. We clinically observed COVID-19 infection lasting longer than the typical course and propose a definition for CAC. Incidence of CAC was highest among patients who received BCDT within 30 days before or 2 weeks after COVID-19 diagnosis. High suspicion for CAC is warranted among patients receiving these therapies. Additional study is needed to better define risk for CAC among varying immunosuppressed populations and determine whether COVID-specific treatments early in disease may benefit these patients.

Disclosures. Hannah Imlay, MD, MS, Gilead Sciences, Inc. (Scientific Research Study Investigator)

494. Characteristics and Outcomes of COVID-19 in Hospitalized Native American Patients: A Single-Site Retrospective Analysis

T Shaffer Jones, BS1; Myles Stone, MD, MPH; Amy Nkam, PharmD, MPH, BCPS1; Nicole A. Bratsch, nC; Trevor N. Thompson, PharmD2; Christopher Jentoft, MD1; Ryan M. Close, MD, MPH2; Whiteriver Service Unit, Indian Health Service, Decatur, Georgia; United States Public Health Service Commissioned Corps, Flagstaff, Arizona; Indian Health Service, Yuma, Arizona; Whiteriver Indian Hospital, Pinetop, Arizona

Methods. We present descriptive data based on chart reviews of COVID-19 patients hospitalized between April 1 and July 31, 2020 at the Whiteriver Service Unit (WRSU), an Indian Health Service site on the Fort Apache Reservation.

Results. Of the 2,262 COVID-19 cases during the observation period, 490 (22%) were hospitalized and 35 (1.6%) died within 28 days. Compared to previous reports, hospitalized patients at WRSU were younger (median age 54), more likely to be female (53% female), and more likely to have comorbidities (92% at least 1, median 2). Patients under 50 (n=200) often had a history of alcohol abuse (51%) or polysubstance abuse (20%). One third of hospitalized patients (34%) were monitored at home and referred for treatment through a high-risk outreach program. Due to our outreach program, which likely decreased the interval between symptom onset and medical treatment, we clinically observed COVID-19 infection lasting longer than the typical course and propose a definition for CAC. Incidence of CAC was highest among patients who received BCDT within 30 days before or 2 weeks after COVID-19 diagnosis. High suspicion for CAC is warranted among patients receiving these therapies. Additional study is needed to better define risk for CAC among varying immunosuppressed populations and determine whether COVID-specific treatments early in disease may benefit these patients.

Disclosures. All Authors: No reported disclosures

495. Evaluation of Antigen Testing for Detection of COVID-19 Vaccine Breakthrough Cases in Long-Term Care

Meghan Linder, MPH1; Sarah Humphrey-King, BS, CHES1; Rebecca Pierce, PhD, MS, BSN1; Sheri L. Hearn, B.S., M.P.H.1; Melissa Sutton, MD, MPH2; Shane Sevey, B.S.1; John Fontana, PhD, HCLD, ARB2; Paul Cielak, MD1; Dat Tran, MD, MS2; Oregon Health Authority, Portland, Oregon; Oregon Health Authority, Oregon State Public Health Lab, Hillsboro, Oregon

Methods. During 2/25/21–5/25/21, OHA supported testing of residents and staff for two outbreaks at a single LTCF. Paired nasal swabs were collected and tested for SARS-CoV-2 by CDC Influenza SARS-CoV-2 Multiplex PCR Assay (molecular test) and Abbott BinaxNOW COVID-19 Ag Card (Ag test) twice weekly during the

Conclusion. Hospitalized patients at WRSU tended to be younger but with more comorbidities than previous studies. This may reflect the fact that NAs tend to acquire comorbidities at younger ages than the general population. This may also reflect the high rates of substance abuse in younger patients, which could be an additional risk factor for severe COVID-19. We believe that the low mortality rates at WRSU are a result of our outreach program, which likely decreased the interval between symptom onset and medical treatment.

Disclosures. All Authors: No reported disclosures

S348 • OFID 2021:8 (Suppl 1) • Abstracts
outbreaks. Participants were considered fully vaccinated if ≥ 14 days had passed since completion of a vaccine series; all others were deemed unvaccinated. A vaccine breakthrough case was defined as a positive Ag or molecular test from a fully vaccinated person's specimen. Performance characteristics of the Ag test were assessed, with molecular test as the reference standard. Cycle threshold (Ct) values were compared by one-sided independent t-tests.

Results. 94 unvaccinated residents and staff provided 563 paired samples; SARS-CoV-2 was detected in 21 (12 by Ag and molecular test, 6 by molecular test only, 3 by Ag test only), yielding Ag test sensitivity of 66.7% (95% CI: 38.8–83.7%) and specificity of 99.4% (95% CI: 99.4–99.8%). Mean Ct values were higher for specimens positive by PCR but negative by Ag than those positive by both (30.0 vs. 20.7, P < .01). 81 vaccinated persons provided 925 paired samples; SARS-CoV-2 was detected in 5 (1 by Ag and molecular test, 4 by molecular test only), yielding Ag test sensitivity of 20% (95% CI: 3.6–62.5%) and specificity of 100% (95% CI: 99.6–100%). Mean Ct values for specimens from vaccinated cases were higher than those from unvaccinated cases (30.2 vs. 23.8, P < .05). The lone Ag-positive breakthrough case had a Ct of 20; all others had Ct > 29.

Conclusion. Ag test performance and reduced sensitivity on specimens with high Ct values found in this population are consistent with published data. Molecular testing maximizes identification of vaccine breakthrough cases. More studies are needed to estimate the proportion of breakthrough cases missed by Ag testing and their risk of transmitting the virus in LTCFs.

Disclosures. All Authors: No reported disclosures

496. Comparison of Severe COVID 19 and Influenza Infections in Pediatric Patients Requiring PICU in Bogota, Colombia

Ivan Felipe Gutiérrez Tobar, n/a; Tatiana Patiño, Pediatrician; Paola Rico, n/a; Nicolas Figueroa, n/a; Juan Pablo Londono-Ruiz, Fellow Pediatric Infectious Diseases; Diana N. Avila, n/a; Mary A. Sanabria, n/a; Angie Vergara, Pediatrician; Paula Gonzalez, n/a; Carolina Rodriguez, n/a; Sandra Beltran, n/a; 1Clinica Infantil Colsubsidio, Clínica Infantil Santa Maria del Lago, Bogotá, Distrito Capital de Bogota, Colombia; 2Clinica Infantil Santa Maria del Lago, Bogotá, Distrito Capital de Bogota, Colombia; 3Clinica Pediatrica Bogota, Bogotá, Distrito Capital de Bogota, Colombia; 4Clinical Infantil Colsubsidio, Bogotá, Distrito Capital de Bogota, Colombia; 5Universidad El Bosque, Bogotá, Distrito Capital de Bogota, Colombia; Fundación Universitaria Sanitas, Bogotá, Distrito Capital de Bogota, Colombia; Universidad del Rosario, Bogotá, Distrito Capital de Bogota, Colombia; 7Clínicas Colsanitas, Bogotá, Distrito Capital de Bogota, Colombia; 8Clinicas Infantil Santa Maria del Lago, Bogotá, Distrito Capital de Bogota, Colombia; 9Clinicas Colsanitas, Bogotá, Distrito Capital de Bogota, Colombia

Coldusidio Investiga

Session: P.23. COVID-19 Special populations (e.g. pregnant women, children, immunocompromised, etc)

Background. COVID 19 infection represents a global threat and now a frequent cause of hospitalization in pediatrics. COVID 19, as well as Influenza virus could have a severe course. There are few studies, and no local or regional information comparing severe disease between COVID 19 and Influenza virus in children.

Methods. Confirmed COVID 19 between March 2020 to October 2021 and influenza infections from Jan-2017 to Dec-2019 were included. Asymptomatic or ambulatory COVID 19 infections were excluded. The main objective was to compare clinical, laboratory and outcome characteristic of PICU admitted patients.

Results. 71 patients were included, 32 (45.1%) with COVID 19 and 39 (54.9%) influenza virus. COVID 19 patients were older than influenza patients: 67 (20.5–143) vs. 10 (2–46) p=0.0002. The majority of influenza patients were younger than two years, with different distributions in COVID 19 patients. Figure 1. Respiratory distress was more frequent in influenza (92.3% vs. 62.5%, p=0.002), but exanthema (28.1% vs 2.6%), shock (68.7% vs. 7.7%) and central nervous system manifestations (40.6% vs. 7.7%) were significantly more common in COVID19 than in Influenza respectively. COVID 19 had lower platelets and higher lymphocyte counts than influenza. There were no differences in treatment, nor deceased either, but Influenza patients had slightly longer hospital stays 12 (7 ~ 23) vs. 9.5 (6–15.5) p=0.1592 than COVID 19 (Table 1).

Conclusion. COVID 19 and influenza severe infections can have some differences including age of presentation. Influenza main manifestation requiring UCIP is respiratory distress, while COVID19 can have other presentations including shock and central nervous manifestation. Lower lymphocyte counts as well as lower platelets were significantly more common in COVID 19 patients. Although there are no unique characteristics of each infection, some particularities could guide clinician to the etiology of the infection.

Disclosures. Ivan Felipe Gutiérrez Tobar, n/a; Pfizer and MSD (Advisor or Review Panel member, Research Grant or Support, Speaker's Bureau, Has received support from Pfizer and MSD for participation in congresses in congresses) Sandra Beltran, n/a; Pfizer (Other Financial or Material Support, Has received support from Pfizer for participation in congresses)

Table 1. Comparison of demographic and clinical characteristics of COVID 19 vs. Influenza patients.

| Characteristics | COVID 19 | Influenza | P-value |
|-----------------|----------|-----------|---------|
| Age in months (Median, IQR) | 67 (20.5–143) | 10 (2–46) | < .0001 |
| Male | 30 (44.5) | 22 (56.1) | .0567 |
| Age categories | | | < .0001 |
| < 2 years | 31 (44.9) | 10 (26.3) | | |
| 2–5 years | 23 (32.9) | 18 (46.2) | | |
| > 5–12 years | 13 (18.3) | 13 (33.3) | | |
| > 12 years | 4 (5.7) | 0 | | |
| Comorbidities | | | .9393 |
| Diabetes | 3 (4.2) | 1 (2.6) | | |
| Requiring invasive mechanical ventilation | 23 (32.4) | 10 (26.3) | .2593 |
| Lymphopenia | 33 (46.5) | 17 (43.6) | | |
| CRP mg/L | 2.7 (2.4–46.1) | 1.7 (2–45.1) | .7441 |
| Blood tests | | | | |
| Complete blood count | | | | |
| Hemoglobin | 11 (9.8–12.4) | 11 (9.8–12.4) | | |
| Platelets | 290 (221–268) | 294 (250–320) | .4831 |
| CK (mg/L) | 26 (8–74) | 37 (20–76) | | |
| CT scan | | | | |
| Pneumonia | 51 (71.2) | 28 (71.8) | .7393 |
| Necrotizing pneumonitis | 16 (22.5) | 13 (33.3) | | |
| Lobar pneumonia | 10 (14.1) | 12 (31.5) | | |
| Abnormal chest X-ray | 51 (71.2) | 35 (92.1) | | |
| Abnormal pleural effusion | 7 (9.9) | 6 (15.8) | | |
| Abnormal cardiac shadow | 2 (2.8) | 2 (5.3) | | |
| Abnormal electrocardiogram | 51 (71.2) | 41 (108.1) | | |
| Abnormal chest X-ray | 51 (71.2) | 35 (92.1) | | |
| Abnormal pleural effusion | 7 (9.9) | 6 (15.8) | | |
| Abnormal cardiac shadow | 2 (2.8) | 2 (5.3) | | |
| Abnormal electrocardiogram | 51 (71.2) | 41 (108.1) | | |
| Length of hospitalization (days) | 9.8 (7–15) | 12 (7–13) | .0320 |

1Welch test; 2Chi-square; 3Fisher